These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 36435690)

  • 1. The development of post-transplant cyclophosphamide: Half a century of translational team science.
    O'Donnell PV; Jones RJ
    Blood Rev; 2023 Nov; 62():101034. PubMed ID: 36435690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allogeneic Blood or Marrow Transplantation with Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Multiple Myeloma.
    Ghosh N; Ye X; Tsai HL; Bolaños-Meade J; Fuchs EJ; Luznik L; Swinnen LJ; Gladstone DE; Ambinder RF; Varadhan R; Shanbhag S; Brodsky RA; Borrello IM; Jones RJ; Matsui W; Huff CA
    Biol Blood Marrow Transplant; 2017 Nov; 23(11):1903-1909. PubMed ID: 28711728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allogeneic blood or marrow transplantation using haploidentical grandchildren donors and post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis.
    Aljawai YM; Tsai HL; Varadhan R; Jones RJ; Imus PH
    Br J Haematol; 2024 Oct; 205(4):1469-1476. PubMed ID: 39099174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation.
    Gaballa S; Ge I; El Fakih R; Brammer JE; Kongtim P; Tomuleasa C; Wang SA; Lee D; Petropoulos D; Cao K; Rondon G; Chen J; Hammerstrom A; Lombardi L; Alatrash G; Korbling M; Oran B; Kebriaei P; Ahmed S; Shah N; Rezvani K; Marin D; Bashir Q; Alousi A; Nieto Y; Qazilbash M; Hosing C; Popat U; Shpall EJ; Khouri I; Champlin RE; Ciurea SO
    Cancer; 2016 Nov; 122(21):3316-3326. PubMed ID: 27404668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Donor HLA mismatch promotes full donor T-cell chimerism in the allogeneic stem cell transplant with reduced-intensity conditioning and post-transplant cyclophosphamide GVHD prophylaxis.
    Cioccio J; Rakszawski K; Zheng H; Nickolich M; Naik S; Wirk B; Rybka W; Ehmann C; Silar B; Vajdic C; Shah N; Tuanquin L; Greiner R; Brown V; Hohl R; Claxton D; Mineishi S; Minagawa K; Shike H
    Ann Hematol; 2023 Mar; 102(3):613-620. PubMed ID: 36527460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is post-transplant cyclophosphamide a true game-changer in allogeneic transplantation: The struggle to unlearn.
    Jones RJ
    Best Pract Res Clin Haematol; 2019 Dec; 32(4):101112. PubMed ID: 31779984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Graft Cryopreservation Does Not Impact Overall Survival after Allogeneic Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis.
    Hamadani M; Zhang MJ; Tang XY; Fei M; Brunstein C; Chhabra S; D'Souza A; Milano F; Phelan R; Saber W; Shaw BE; Weisdorf D; Devine SM; Horowitz MM
    Biol Blood Marrow Transplant; 2020 Jul; 26(7):1312-1317. PubMed ID: 32283185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allogeneic Blood or Marrow Transplantation with Post-Transplantation Cyclophosphamide for Peripheral T Cell Lymphoma: The Importance of Graft Source.
    Sterling CH; Hughes MS; Tsai HL; Yarkony K; Fuchs EJ; Swinnen LJ; Paul S; Bolaños-Meade J; Luznik L; Imus PH; Ali SA; Jain T; Ambinder A; DeZern A; Huff CA; Gocke CB; Varadhan R; Wagner-Johnston N; Jones RJ; Ambinder RF
    Transplant Cell Ther; 2023 Apr; 29(4):267.e1-267.e5. PubMed ID: 36549386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-World Data Showing Trends and Outcomes by Race and Ethnicity in Allogeneic Hematopoietic Cell Transplantation: A Report from the Center for International Blood and Marrow Transplant Research.
    Auletta JJ; Kou J; Chen M; Bolon YT; Broglie L; Bupp C; Christianson D; Cusatis RN; Devine SM; Eapen M; Hamadani M; Hengen M; Lee SJ; Moskop A; Page KM; Pasquini MC; Perez WS; Phelan R; Riches ML; Rizzo JD; Saber W; Spellman SR; Stefanski HE; Steinert P; Tuschl E; Yusuf R; Zhang MJ; Shaw BE
    Transplant Cell Ther; 2023 Jun; 29(6):346.e1-346.e10. PubMed ID: 36924931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Total Body Irradiation and Fludarabine with Post-Transplantation Cyclophosphamide for Mismatched Related or Unrelated Donor Hematopoietic Cell Transplantation.
    Arslan S; Desai A; Yang D; Mokhtari S; Tiemann K; Otoukesh S; Samara Y; Blackmon A; Agrawal V; Pourhassan H; Amanam I; Ball B; Koller P; Salhotra A; Aribi A; Becker P; Curtin P; Artz A; Aldoss I; Ali H; Stewart F; Smith E; Stein A; Marcucci G; Forman SJ; Nakamura R; Al Malki MM
    Transplant Cell Ther; 2024 Oct; 30(10):1013.e1-1013.e12. PubMed ID: 39122188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Posttransplant cyclophosphamide-based anti-graft-vs-host disease prophylaxis in patients with acute lymphoblastic leukemia treated in complete remission with allogeneic hematopoietic cell transplantation from human leukocyte antigen-mismatched unrelated donors versus haploidentical donors: A study on behalf of the ALWP of the EBMT.
    Nagler A; Labopin M; Arat M; Reményi P; Koc Y; Blaise D; Angelucci E; Vydra J; Kulagin A; Socié G; Rovira M; Sica S; Aljurf M; Gülbas Z; Kröger N; Brissot E; Peric Z; Giebel S; Ciceri F; Mohty M
    Cancer; 2022 Nov; 128(22):3959-3968. PubMed ID: 36110063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis in HLA-Matched and Haploidentical Donor Transplantation for Patients with Hodgkin Lymphoma: A Comparative Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation.
    Montoro J; Boumendil A; Finel H; Bramanti S; Castagna L; Blaise D; Dominietto A; Kulagin A; Yakoub-Agha I; Tbakhi A; Solano C; Giebel S; Gulbas Z; López Corral L; Pérez-Simón JA; Díez Martín JL; Sanz J; Farina L; Koc Y; Socié G; Arat M; Jurado M; Bermudez A; Labussière-Wallet H; Villalba M; Ciceri F; Martinez C; Nagler A; Sureda A; Glass B
    Transplant Cell Ther; 2024 Feb; 30(2):210.e1-210.e14. PubMed ID: 38043802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxis.
    Gooptu M; Romee R; St Martin A; Arora M; Al Malki M; Antin JH; Bredeson CN; Brunstein CG; Chhabra S; Fuchs EJ; Ghosh N; Grunwald MR; Kanakry CG; Kekre N; McGuirk JP; McNiece IK; Mehta RS; Mielcarek M; Milano F; Modi D; Reshef R; Solomon SR; Schroeder MA; Waller EK; Inamoto Y; Soiffer RJ; Eapen M
    Blood; 2021 Jul; 138(3):273-282. PubMed ID: 34292325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduced Intensity Bone Marrow Transplantation with Post-Transplant Cyclophosphamide for Pediatric Inherited Immune Deficiencies and Bone Marrow Failure Syndromes.
    Klein OR; Bapty S; Lederman HM; Younger MEM; Zambidis ET; Jones RJ; Cooke KR; Symons HJ
    J Clin Immunol; 2021 Feb; 41(2):414-426. PubMed ID: 33159275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms of Graft-versus-Host Disease Prevention by Post-transplantation Cyclophosphamide: An Evolving Understanding.
    Nunes NS; Kanakry CG
    Front Immunol; 2019; 10():2668. PubMed ID: 31849930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Post-transplant high-dose cyclophosphamide for the prevention of graft-versus-host disease.
    Al-Homsi AS; Roy TS; Cole K; Feng Y; Duffner U
    Biol Blood Marrow Transplant; 2015 Apr; 21(4):604-11. PubMed ID: 25240817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
    Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Posttransplant cyclophosphamide beyond haploidentical transplantation.
    Arcuri LJ; Ribeiro AAF; Hamerschlak N; Kerbauy MN
    Ann Hematol; 2024 May; 103(5):1483-1491. PubMed ID: 37261557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single Antigen-Mismatched Unrelated Hematopoietic Stem Cell Transplantation Using High-Dose Post-Transplantation Cyclophosphamide Is a Suitable Alternative for Patients Lacking HLA-Matched Donors.
    Jorge AS; Suárez-Lledó M; Pereira A; Gutierrez G; Fernández-Avilés F; Rosiñol L; Llobet N; Solano T; Urbano-Ispízua Á; Rovira M; Martínez C
    Biol Blood Marrow Transplant; 2018 Jun; 24(6):1196-1202. PubMed ID: 29410343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Posttransplantation Cyclophosphamide- and Sirolimus-Based Graft-Versus-Host-Disease Prophylaxis in Allogeneic Stem Cell Transplant.
    Greco R; Lorentino F; Albanese S; Lupo Stanghellini MT; Giglio F; Piemontese S; Clerici D; Lazzari L; Marcatti M; Mastaglio S; Xue E; Farina F; Pavesi F; Assanelli A; Carrabba MG; Marktel S; Vago L; Bonini C; Corti C; Bernardi M; Ciceri F; Peccatori J
    Transplant Cell Ther; 2021 Sep; 27(9):776.e1-776.e13. PubMed ID: 34087452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.